301 related articles for article (PubMed ID: 26811176)
1. A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities.
Lu D; Lu T; Stroh M; Graham RA; Agarwal P; Musib L; Li CC; Lum BL; Joshi A
Cancer Chemother Pharmacol; 2016 Mar; 77(3):459-76. PubMed ID: 26811176
[TBL] [Abstract][Full Text] [Related]
2. Lessons Learned: Dose Selection of Small Molecule-Targeted Oncology Drugs.
Bullock JM; Rahman A; Liu Q
Clin Cancer Res; 2016 Jun; 22(11):2630-8. PubMed ID: 27250934
[TBL] [Abstract][Full Text] [Related]
3. Factors That Influence FDA Decisions for Postmarketing Requirements and Commitments During Review of Oncology Products.
Hyogo A; Kaneko M; Narukawa M
J Oncol Pract; 2018 Jan; 14(1):e34-e41. PubMed ID: 29136389
[TBL] [Abstract][Full Text] [Related]
4. Starting dose selection and dose escalation for oncology small molecule first-in-patient trials: learnings from a survey of FDA-approved drugs.
Mittapalli RK; Yin D; Beaupre D; Palaparthy R
Cancer Chemother Pharmacol; 2021 Jan; 87(1):23-30. PubMed ID: 33237334
[TBL] [Abstract][Full Text] [Related]
5. Rendering the 3 + 3 Design to Rest: More Efficient Approaches to Oncology Dose-Finding Trials in the Era of Targeted Therapy.
Nie L; Rubin EH; Mehrotra N; Pinheiro J; Fernandes LL; Roy A; Bailey S; de Alwis DP
Clin Cancer Res; 2016 Jun; 22(11):2623-9. PubMed ID: 27250933
[TBL] [Abstract][Full Text] [Related]
6. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
Infante JR; Camidge DR; Mileshkin LR; Chen EX; Hicks RJ; Rischin D; Fingert H; Pierce KJ; Xu H; Roberts WG; Shreeve SM; Burris HA; Siu LL
J Clin Oncol; 2012 May; 30(13):1527-33. PubMed ID: 22454420
[TBL] [Abstract][Full Text] [Related]
7. US FDA's Dose Optimization Postmarketing Requirements and Commitments of Oncology Approvals and the Impact on Product Labels from 2010 to 2022: An Emerging Landscape from Traditional to Novel Therapies.
Gendy JM; Nomura N; Stuart JN; Blumenthal G
Ther Innov Regul Sci; 2024 Mar; 58(2):380-386. PubMed ID: 38182940
[TBL] [Abstract][Full Text] [Related]
8. Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials.
Shepshelovich D; Tibau A; Goldvaser H; Molto C; Ocana A; Seruga B; Amir E
J Clin Oncol; 2018 Jun; 36(18):1798-1804. PubMed ID: 29641296
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials.
Gupta S; Hunsberger S; Boerner SA; Rubinstein L; Royds R; Ivy P; LoRusso P
J Natl Cancer Inst; 2012 Dec; 104(24):1860-6. PubMed ID: 23169991
[TBL] [Abstract][Full Text] [Related]
10. Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example.
Sachs JR; Mayawala K; Gadamsetty S; Kang SP; de Alwis DP
Clin Cancer Res; 2016 Mar; 22(6):1318-24. PubMed ID: 26597302
[TBL] [Abstract][Full Text] [Related]
11. Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life Cycle.
Jänne PA; Kim G; Shaw AT; Sridhara R; Pazdur R; McKee AE
Clin Cancer Res; 2016 Jun; 22(11):2613-7. PubMed ID: 27250931
[TBL] [Abstract][Full Text] [Related]
12. Oncology dose optimization paradigms: knowledge gained and extrapolated from approved oncology therapeutics.
Mittapalli RK; Guo C; Drescher SK; Yin D
Cancer Chemother Pharmacol; 2022 Sep; 90(3):207-216. PubMed ID: 35965268
[TBL] [Abstract][Full Text] [Related]
13. Towards using a full spectrum of early clinical trial data: a retrospective analysis to compare potential longitudinal categorical models for molecular targeted therapies in oncology.
Colin P; Micallef S; Delattre M; Mancini P; Parent E
Stat Med; 2015 Sep; 34(22):2999-3016. PubMed ID: 26059319
[TBL] [Abstract][Full Text] [Related]
14. Differences in maximum tolerated doses and approval doses of molecularly targeted oncology drug between Japan and Western countries.
Maeda H; Kurokawa T
Invest New Drugs; 2014 Aug; 32(4):661-9. PubMed ID: 24615632
[TBL] [Abstract][Full Text] [Related]
15. Optimizing benefit/risk in oncology: Review of post-marketing dose optimization and reflections on the road ahead.
Soltantabar P; Lon HK; Parivar K; Wang DD; Elmeliegy M
Crit Rev Oncol Hematol; 2023 Feb; 182():103913. PubMed ID: 36681205
[TBL] [Abstract][Full Text] [Related]
16. Exposure- and Dose-response Analyses in Dose Selection and Labeling of FDA-approved Biologics.
Ogasawara K; Breder CD; Lin DH; Alexander GC
Clin Ther; 2018 Jan; 40(1):95-102.e2. PubMed ID: 29273471
[TBL] [Abstract][Full Text] [Related]
17. Rare cancer trial design: lessons from FDA approvals.
Gaddipati H; Liu K; Pariser A; Pazdur R
Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
[TBL] [Abstract][Full Text] [Related]
18. Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013.
Nikanjam M; Liu S; Kurzrock R
Int J Cancer; 2016 Nov; 139(9):2135-41. PubMed ID: 27389805
[TBL] [Abstract][Full Text] [Related]
19. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse.
Jain RK; Lee JJ; Hong D; Markman M; Gong J; Naing A; Wheler J; Kurzrock R
Clin Cancer Res; 2010 Feb; 16(4):1289-97. PubMed ID: 20145187
[TBL] [Abstract][Full Text] [Related]
20. Premarket Evidence and Postmarketing Requirements for Real-Time Oncology Review Indication Approvals.
Mooghali M; Mohammad A; Wallach JD; Mitchell AP; Ross JS; Ramachandran R
JAMA Netw Open; 2024 May; 7(5):e249233. PubMed ID: 38691363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
